Rami Alzhrani

TL;DR: The current landscape of the PD-1/PD-L1 mechanistic role in tumor immune evasion and therapeutic outcome for cancer treatment is reviewed and the current progress in clinical trials, combination of drug therapy with immunotherapy, safety, and future of check point inhibitors for multiple types of cancer are reviewed.

TL;DR: The role of multifunctional polymeric, lipid, metallic and cell based nanoparticles for improving current immunotherapy and the function of host immune stimulatory signals and tumor immunotherapies can be improved by repurposing of nanomedicine platform are summarized.

TL;DR: Progress made in the use of nanotherapeutics as delivery tools for PSs to improve their cancer cellular uptake and their toxic properties and, therefore, the therapeutic impact of PDT is discussed.

TL;DR: In this article, the authors used Sorafenib (Sor) in combination with tumor hypoxia directed nanoparticle (NP) loaded with a new class of apoptosis inducer, CFM 416 (C416), which is designed to selectively deliver the payload to the hypoxic tumor (core), provoke superior cell death in parental (WT) and Everolimus-resistant (Evrres) RCC and selectively downmodulate tumorigenic M2-macrophage Copper-free ‘click ’ chemistry was utilized for conjugating SMA-T

TL;DR: It is concluded that ENIs are better than SCIs and could be utilized as a potential delivery system for treating anterior segment ocular diseases.